BioEclipse Therapeutics Announces First Patient Dosed in Phase 1 Dose-Escalation Clinical Trial of CRX100 in Refractory Solid Tumors
Share this article Share this article Mountain View, Calif., March 5, 2021 /PRNewswire/ -- BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing next-generation cancer immunotherapies, announced today the administration of the first dose of CRX100 to a volunteer in the ongoing Phase 1 clinical trial in patients with refractory solid tumors. The trial is a first-in-human study for CRX100, BioEclipse's lead investigational drug candidate, an intravenously delivered, multi-mechanistic therapy designed to target and ...
Source: prnewswire.com